Introduction: The safety and efficacy of blinatumomab, a CD19/CD3 bispecific T-cell engager (BiTE®) molecule, was evaluated in an expansion cohort of the phase 1b/2 study (NCT02412306) in Japanese adult (n = 14) and pediatric (n = 17) patients with relapsed/refractory Philadelphia-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). Materials and methods: Globally recommended blinatumomab doses were administered to adult (9–28 μg/day) and pediatric (5–15 μg/m2/day) patients. Primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) and treatment-related AEs. Results: All adult and pediatric patients experienced ≥1 TEAE. Grade ≥3 TEAEs were observed in 11 (79%) adult and 15 (88%) pediatric patients. Blinatumomab was discontinued in 1 (6%) pediatric patient due to treatment-related grade 4 cytokine release syndrome. Fatal AEs such as disease progression and multiple-organ dysfunction syndrome, which were not treatment-related, were reported in 2 (12%) pediatric patients. Eleven (79%) adults achieved complete remission (CR)/CR with partial hematological recovery (CRh) within the first two blinatumomab cycles. Nine of 10 adult patients with CR/CRh and evaluable minimal residual disease (MRD) achieved MRD response. CR/CRh was achieved by 5 (29%) pediatric patients, of which two had MRD response. Conclusion: In conclusion, blinatumomab was safe and efficacious in Japanese patients with relapsed/refractory BCP ALL.

1.
Terwilliger
T
,
Abdul-Hay
M
.
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
.
Blood Cancer J
.
2017 Jun 30
;
7
(
6
):
e577
. .
2.
Jabbour
E
,
O’Brien
S
,
Konopleva
M
,
Kantarjian
H
.
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
.
Cancer
.
2015 Aug 1
;
121
(
15
):
2517
28
. .
3.
Fielding
AK
,
Richards
SM
,
Chopra
R
,
Lazarus
HM
,
Litzow
MR
,
Buck
G
,
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
.
Blood
.
2007 Feb 1
;
109
(
3
):
944
50
. .
4.
Tavernier
E
,
Boiron
JM
,
Huguet
F
,
Bradstock
K
,
Vey
N
,
Kovacsovics
T
,
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
.
Leukemia
.
2007 Sep
;
21
(
9
):
1907
14
. .
5.
Thomas
DA
,
O'Brien
S
,
Faderl
S
,
Garcia-Manero
G
,
Ferrajoli
A
,
Wierda
W
,
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
.
J Clin Oncol
.
2010 Aug 20
;
28
(
24
):
3880
9
. .
6.
Stock
W
,
Johnson
JL
,
Stone
RM
,
Kolitz
JE
,
Powell
BL
,
Wetzler
M
,
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802
.
Cancer
.
2013 Jan 1
;
119
(
1
):
90
8
. .
7.
Schauer
P
,
Arlin
ZA
,
Mertelsmann
R
,
Cirrincione
C
,
Friedman
A
,
Gee
TS
,
Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols
.
J Clin Oncol
.
1983 Aug
;
1
(
8
):
462
70
. .
8.
Larson
RA
,
Dodge
RK
,
Burns
CP
,
Lee
EJ
,
Stone
RM
,
Schulman
P
,
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811
.
Blood
.
1995 Apr 15
;
85
(
8
):
2025
37
. .
9.
Gökbuget
N
,
Hoelzer
D
,
Arnold
R
,
Böhme
A
,
Bartram
CR
,
Freund
M
,
Treatment of adult ALL according to protocols of the German multicenter study group for adult ALL (GMALL)
.
Hematol Oncol Clin North Am
.
2000 Dec
;
14
(
6
):
1307
25, ix
. .
10.
Annino
L
,
Vegna
ML
,
Camera
A
,
Specchia
G
,
Visani
G
,
Fioritoni
G
,
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study
.
Blood
.
2002 Feb 1
;
99
(
3
):
863
71
. .
11.
Linker
C
,
Damon
L
,
Ries
C
,
Navarro
W
.
Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia
.
J Clin Oncol
.
2002 May 15
;
20
(
10
):
2464
71
. .
12.
Takeuchi
J
,
Kyo
T
,
Naito
K
,
Sao
H
,
Takahashi
M
,
Miyawaki
S
,
Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study
.
Leukemia
.
2002 Jul
;
16
(
7
):
1259
66
. .
13.
Kantarjian
H
,
Thomas
D
,
O’Brien
S
,
Cortes
J
,
Giles
F
,
Jeha
S
,
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
.
Cancer
.
2004 Dec 15
;
101
(
12
):
2788
801
. .
14.
Rowe
JM
,
Buck
G
,
Burnett
AK
,
Chopra
R
,
Wiernik
PH
,
Richards
SM
,
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
.
Blood
.
2005 Dec 1
;
106
(
12
):
3760
7
. .
15.
Oriol
A
,
Vives
S
,
Hernández-Rivas
JM
,
Tormo
M
,
Heras
I
,
Rivas
C
,
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
.
Haematologica
.
2010 Apr
;
95
(
4
):
589
96
. .
16.
Gökbuget
N
,
Stanze
D
,
Beck
J
,
Diedrich
H
,
Horst
HA
,
Hüttmann
A
,
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
.
Blood
.
2012 Sep 6
;
120
(
10
):
2032
41
. .
17.
Stiller
CA
,
Eatock
EM
.
Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994
.
Arch Dis Child
.
1999 Sep
;
81
(
3
):
202
8
. .
18.
Veerman
AJ
,
Kamps
WA
,
van den Berg
H
,
van den Berg
E
,
Bökkerink
JP
,
Bruin
MC
,
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004)
.
Lancet Oncol
.
2009 Oct
;
10
(
10
):
957
66
. .
19.
Conter
V
,
Aricò
M
,
Basso
G
,
Biondi
A
,
Barisone
E
,
Messina
C
,
Long-term results of the Italian association of pediatric hematology and oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia
.
Leukemia
.
2010 Feb
;
24
(
2
):
255
64
. .
20.
Möricke
A
,
Zimmermann
M
,
Reiter
A
,
Henze
G
,
Schrauder
A
,
Gadner
H
,
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000
.
Leukemia
.
2010 Feb
;
24
(
2
):
265
84
. .
21.
Schmiegelow
K
,
Forestier
E
,
Hellebostad
M
,
Heyman
M
,
Kristinsson
J
,
Söderhäll
S
,
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia
.
Leukemia
.
2010 Feb
;
24
(
2
):
345
54
. .
22.
Hunger
SP
,
Lu
X
,
Devidas
M
,
Camitta
BM
,
Gaynon
PS
,
Winick
NJ
,
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group
.
J Clin Oncol
.
2012 May 10
;
30
(
14
):
1663
9
. .
23.
Gatta
G
,
Rossi
S
,
Foschi
R
,
Trama
A
,
Marcos-Gragera
R
,
Pastore
G
,
Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002
.
Haematologica
.
2013 May
;
98
(
5
):
744
52
. .
24.
Vrooman
LM
,
Stevenson
KE
,
Supko
JG
,
O'Brien
J
,
Dahlberg
SE
,
Asselin
BL
,
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study: Dana-Farber Cancer Institute ALL Consortium Protocol 00-01
.
J Clin Oncol
.
2013 Mar 20
;
31
(
9
):
1202
10
. .
25.
Liu
HC
,
Yeh
TC
,
Hou
JY
,
Chen
KH
,
Huang
TH
,
Chang
CY
,
Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia
.
J Clin Oncol
.
2014 Jun 10
;
32
(
17
):
1825
9
. .
26.
Ma
H
,
Sun
H
,
Sun
X
.
Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis
.
Sci Rep
.
2014 Feb 27
;
4
(
1
):
4227
. .
27.
Pui
CH
,
Pei
D
,
Campana
D
,
Cheng
C
,
Sandlund
JT
,
Bowman
WP
,
A revised definition for cure of childhood acute lymphoblastic leukemia
.
Leukemia
.
2014 Dec
;
28
(
12
):
2336
43
. .
28.
Stary
J
,
Zimmermann
M
,
Campbell
M
,
Castillo
L
,
Dibar
E
,
Donska
S
,
Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002
.
J Clin Oncol
.
2014 Jan 20
;
32
(
3
):
174
84
. .
29.
Vora
A
,
Goulden
N
,
Mitchell
C
,
Hancock
J
,
Hough
R
,
Rowntree
C
,
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
.
Lancet Oncol
.
2014 Jul
;
15
(
8
):
809
18
. .
30.
Ko
RH
,
Ji
L
,
Barnette
P
,
Bostrom
B
,
Hutchinson
R
,
Raetz
E
,
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study
.
J Clin Oncol
.
2010 Feb 1
;
28
(
4
):
648
54
. .
31.
von Stackelberg
A
,
Völzke
E
,
Kühl
JS
,
Seeger
K
,
Schrauder
A
,
Escherich
G
,
Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group
.
Eur J Cancer
.
2011 Jan
;
47
(
1
):
90
7
. .
32.
Hangai
M
,
Urayama
KY
,
Tanaka
J
,
Kato
K
,
Nishiwaki
S
,
Koh
K
,
Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adolescents and young adults
.
Biol Blood Marrow Transplant
.
2019
;
25
(
8
):
1597
602
. .
33.
Bargou
R
,
Leo
E
,
Zugmaier
G
,
Klinger
M
,
Goebeler
M
,
Knop
S
,
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
.
Science
.
2008 Aug 15
;
321
(
5891
):
974
7
. .
34.
Jen
EY
,
Xu
Q
,
Schetter
A
,
Przepiorka
D
,
Shen
YL
,
Roscoe
D
,
FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease
.
Clin Cancer Res
.
2019 Jan 15
;
25
(
2
):
473
7
. .
35.
BLINCYTO® (blinatumomab) approved In Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia
.
AMGEN®
.
2018
.
36.
Kiyoi
H
,
Morris
JD
,
Oh
I
,
Maeda
Y
,
Minami
H
,
Miyamoto
T
,
Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia
.
Cancer Sci
.
2020 Apr
;
111
(
4
):
1314
23
. .
37.
Horibe
K
,
Morris
JD
,
Tuglus
CA
,
Dos Santos
C
,
Kalabus
J
,
Anderson
A
,
A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
.
Int J Hematol
.
2020 Aug
;
112
(
2
):
223
33
. .
38.
Topp
MS
,
Gökbuget
N
,
Stein
AS
,
Zugmaier
G
,
O'Brien
S
,
Bargou
RC
,
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
.
Lancet Oncol
.
2015 Jan
;
16
(
1
):
57
66
. .
39.
von Stackelberg
A
,
Locatelli
F
,
Zugmaier
G
,
Handgretinger
R
,
Trippett
TM
,
Rizzari
C
,
Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
.
J Clin Oncol
.
2016 Dec 20
;
34
(
36
):
4381
9
. .
40.
Kantarjian
H
,
Stein
A
,
Gökbuget
N
,
Fielding
AK
,
Schuh
AC
,
Ribera
JM
,
Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
.
N Engl J Med
.
2017 Mar 2
;
376
(
9
):
836
47
. .
41.
Locatelli
F
,
Zugmaier
G
,
Mergen
N
,
Bader
P
,
Jeha
S
,
Schlegel
PG
,
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
.
Blood Cancer J
.
2020 Jul 24
;
10
(
7
):
77
. .
42.
Wei
AH
,
Ribera
JM
,
Larson
RA
,
Ritchie
D
,
Ghobadi
A
,
Chen
Y
,
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
.
Leukemia
.
2021 Aug
;
35
(
8
):
2220
31
. .
43.
Kobayashi
Y
,
Oh
I
,
Miyamoto
T
,
Lee
WS
,
Iida
H
,
Minami
H
,
Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
.
Asia Pac J Clin Oncol
.
2022
;
18
(
3
):
311
8
. .
44.
Gökbuget
N
,
Kantarjian
HM
,
Brüggemann
M
,
Stein
AS
,
Bargou
RC
,
Dombret
H
,
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
.
Blood Adv
.
2019 Oct 22
;
3
(
20
):
3033
7
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.